NCT03273192View on ClinicalTrials.gov

A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

74

Participants

Timeline

Start Date

October 22, 2016

Primary Completion Date

August 6, 2017

Study Completion Date

August 6, 2017

Conditions

BioequivalencePhase 1

Interventions

DRUG

Adalimumab

A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.

Trial Locations (1)

1425614985

Orchidpharmed PK/PD site, Tehran

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Cinnagen

INDUSTRY